Paul Conyngham designed a personalized mRNA cancer vaccine for his dog in weeks. The obvious question everyone asks: when can humans get the same thing? The answer is both encouraging and nuanced.
The biological process is identical for dogs and humans. Tumor sequencing, baseline genome comparison, neoantigen identification, MHC binding prediction, and mRNA vaccine design all work the same way regardless of species. The proteins are different, the MHC molecules are different, but the workflow is the same.
Veterinary treatments face far lighter regulatory requirements than human medicine. Conyngham could go from concept to injection in weeks because there was no equivalent of FDA Phase I-III clinical trials for a compassionate veterinary use case. For humans, the regulatory path requires years of clinical trials demonstrating safety and efficacy.
BioNTech, Moderna, and multiple academic medical centers are running clinical trials of personalized mRNA cancer vaccines right now. Results are promising — six-year remission data for breast cancer, 49% reduction in melanoma recurrence, ongoing trials for pancreatic and colorectal cancers. First commercial approvals are expected by 2029.
You can't get a personalized cancer vaccine today. But you can prepare for the day you can — or the day you need one. Every personalized treatment starts with your complete genome and MHC profile. Having both stored and ready means that when these treatments become available, you're not starting from zero. You're starting from ready.
Related: How One Man Used AI to Save His Dog · mRNA Cancer Vaccines in 2026 · View Pricing
Ready to secure your genome?
Join the Waitlist